

2024 Areas of Interest for Nemtabrutinib

Clinical:

- Primary focus of the program in 2024 is on specific lymphomas (DLBCL, Follicular Lymphoma, Marginal Zone Lymphoma, and Waldenstrom's Macroglobulinemia) and cGVHD
- The following lymphomas are of secondary focus in 2024: CLL/SLL, MCL and Richter's Transformation; the program remains interested in innovative concepts for these lymphomas but it is strongly recommended that investigators discuss their concepts with the field or country team before submission
- Combinations with SOC, or other novel therapies (eg, CAR-T, BCL2 inhibitors, polyspecific antibodies, ADCs)
- Assess mechanisms of innate and/or acquired resistance development in a clinical setting, including time to mutation development, impact on clinical outcome, and characterization of specific resistance mechanisms
- The following are currently not of interest in 2024 – Primary CNS lymphoma, autoimmune conditions, solid tumors

Pre-Clinical:

- Establish novel mechanisms of intrinsic and/or acquired resistance to nemtabrutinib that occur independent or concurrent with previously described mutations.
- Evaluate hematological or non-hematological disease states beyond CLL/SLL and mantle cell lymphoma that may be susceptible to treatment with nemtabrutinib, either as a single agent or in novel combinations.
- Identify additive and or antagonistic mechanisms of action between nemtabrutinib and novel combination partners.
- Nominate biomarkers for sensitivity to single agent or combination treatment of nemtabrutinib with other available or developing treatments. Studies that clarify mechanisms by which sensitivity to nemtabrutinib is distinguished from other BTK inhibitors are of particular interest.
- Evaluate mechanisms of intrinsic or acquired resistance to current treatments for CLL/SLL or mantle cell lymphoma that inform the appropriate use of nemtabrutinib.

Special Note: Diversity & Inclusion

We seek to foster diverse and inclusive representation within the individual Areas of Interest for each tumor type, and so encourage study concept submissions across our program which:

- Specifically focus on the outcome disparities in underrepresented populations
- Are led by non-academic programs/institutions
- Are conducted in under-represented regions or countries